

Supplemental Material - Neighbourhood disadvantage impacts on pulmonary function in patients with sarcoidosis

Gillian C. Goobie, MD^{1,2,3}; Christopher J. Ryerson, MD, MAS^{4,5}; Kerri A. Johannson, MD, MPH⁶; Erin Schikowski, MD⁷; Nasreen Khalil, MD⁴; Veronica Marcoux, MD⁸; Deborah Assayag, MD⁹; H el ene Manganas, MD¹⁰; Jolene H. Fisher, MD¹¹; Martin R.J. Kolb, MD, PhD¹²; Kevin F. Gibson, MD^{2,13}; Daniel J. Kass, MD^{2,13}; Yingze Zhang, PhD¹³; Kathleen O. Lindell, RN, PhD^{2,14*}; S. Mehdi Nouraie, MD, PhD^{13*}

1. Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, U.S.A. Email: goobiegc@upmc.edu.
2. Simmons Center for Interstitial Lung Disease, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, U.S.A.
3. Clinician Investigator Program, Department of Medicine, University of British Columbia, Vancouver, B.C., Canada.
4. Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, B.C., Canada. Email: chris.ryerson@hli.ubc.ca, nkhalil@mail.ubc.ca.
5. Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, B.C., Canada.
6. Division of Respiratory Medicine, Department of Medicine, University of Calgary, Calgary, AB, Canada. Email: kerri.johannson@albertahealthservices.ca.
7. Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, U.S.A. Email: schikowskiem@upmc.edu.
8. Division of Respiriology, Critical Care and Sleep Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada. Email: vsm940@mail.usask.ca.
9. Division of Respiratory Medicine, Department of Medicine and Health Sciences, McGill University, Montreal, QC, Canada. Email: deborah.assayag@mcgill.ca.
10. D epartement de M edecine, Centre Hospitalier de l'Universit e de Montr eal, Montreal, QC, Canada. Email: helene.manganas.med@ssss.gouv.qc.ca.
11. Division of Respiriology, Department of Medicine, University of Toronto, Toronto, ON, Canada. Email: jolene.fisher@uhn.ca.
12. Department of Medicine, Firestone Institute for Respiratory Health, The Research Institute of St. Joe's Hamilton, St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada. Email: kolbm@mcmaster.ca.
13. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, U.S.A. Emails: gibsonkf@upmc.edu, kassd2@upmc.edu, zhanyx@upmc.edu, nouraies@upmc.edu.
14. College of Nursing, Medical University of South Carolina, Charleston, SC, U.S.A. Email: lindellk@musc.edu.

*Denotes co-senior authorship

ORCID IDs: 0000-0001-7982-5635 (G.C.G.); 0000-0001-6597-7830 (D.J.K.); 0000-0001-6947-2901 (Y.Z.); 0000-0002-2927-0659 (K.O.L.); 0000-0001-7465-0581 (M.N.).

Table E1: Baseline characteristics in U.S. and Canadian cohorts broken down by ADI or CIMD quartile. Abbreviations: ADI, area deprivation index; CIMD, Canadian index of multiple deprivation; D_LCO, diffusion capacity for carbon monoxide; FVC, forced vital capacity; IQR, interquartile range; Q1-Q4, Quartiles 1-4.

Patient Characteristics	U.S. Cohort				Canadian Cohort			
	ADI Q1 (1 to 49)	ADI Q2 (50 to 67)	ADI Q3 (68 to 83)	ADI Q4 (84 to 100)	CIMD Q1 (-1.1 to -0.5)	CIMD Q2 (-0.5 to -0.1)	CIMD Q3 (-0.1 to 0.2)	CIMD Q4 (0.2 to 2.5)
	N = 125	N = 116	N = 128	N = 108	N = 31	N = 30	N = 30	N = 31
Age at diagnosis, median (IQR), years	49 (43, 55)	50 (40, 59)	50 (43, 58)	48 (40, 55)	50 (46, 60)	55 (45, 64)	51 (43, 60)	54 (48, 60)
Year of diagnosis, median (IQR)	2010 (2006, 2013)	2010 (2006, 2013)	2010 (2006, 2013)	2009 (2006, 2012)	2016 (2012, 2018)	2016 (2014, 2017)	2016 (2014, 2018)	2015 (2011, 2017)
Male sex, n (%)	68 (54%)	49 (42%)	51 (40%)	39 (36%)	20 (65%)	14 (47%)	19 (63%)	14 (45%)
Self-reported Race (n, %)								
White	101 (81%)	99 (85%)	101 (79%)	52 (48%)	29 (94%)	28 (93%)	26 (87%)	29 (94%)
Black	21 (17%)	15 (13%)	21 (16%)	53 (49%)	1 (3%)	0 (0%)	2 (7%)	0 (0%)
Asian	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (3%)	1 (3%)	0 (0%)	2 (6%)
Indigenous*	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (3%)	0 (0%)
Unknown	2 (2%)	2 (2%)	5 (4%)	3 (3%)	0 (0%)	1 (3%)	1 (3%)	0 (0%)
Smoker (n, %)								
Never	71 (57%)	64 (55%)	72 (56%)	49 (45%)	18 (58%)	15 (50%)	12 (40%)	16 (52%)
Former	43 (34%)	35 (30%)	35 (27%)	45 (42%)	12 (39%)	13 (43%)	14 (47%)	12 (39%)
Current	9 (7%)	9 (8%)	9 (7%)	8 (7%)	1 (3%)	2 (7%)	4 (13%)	3 (9%)
Unknown	2 (2%)	8 (7%)	12 (10%)	6 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
ADI or CIMD, median score (IQR)	35 (27, 43)	59 (55, 63)	75 (71, 80)	91 (87, 96)	-0.6 (-0.8, -0.6)	-0.3 (-0.4, -0.2)	0.1 (0.0, 0.2)	0.5 (0.4, 0.7)
Baseline % Predicted FVC, median (IQR)	88 (71, 96)	85 (72, 96)	81 (70, 94)	78 (66, 91)	87 (76, 96)	87 (73, 96)	82 (69, 95)	92 (73, 101)
Baseline % Predicted D_LCO, median (IQR)	79 (66, 99)	76 (61, 91)	75 (63, 88)	66 (54, 82)	87 (75, 93)	85 (78, 99)	78 (65, 86)	81 (72, 89)
Follow-up Duration, median (IQR), years	8.8 (5.2, 12.7)	8.0 (4.9, 12.0)	8.0 (4.3, 12.1)	8.4 (4.2, 13.1)	4.1 (2.1, 8.2)	3.4 (2.7, 5.8)	4.4 (2.3, 5.9)	5.2 (3.1, 9.4)
Cause of censoring, n (%)								
Death	12 (10%)	13 (11%)	14 (11%)	12 (11%)	0 (0%)	0 (0%)	3 (10%)	1 (3%)
Lung Transplantation	3 (2%)	4 (4%)	4 (3%)	4 (4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

*Includes Native American, American Indian, Alaskan First Nations, & other Indigenous persons in the U.S.; First Nations, Métis, Inuit, and other Indigenous persons in Canada.

Table E2: Baseline immunosuppressant treatment breakdown. If a patient received a treatment course of corticosteroids (oral or intravenous), steroid-sparing agents, or biologics prior to registry enrollment, these are listed in the table below.

Simmons Cohort		CARE-PF Cohort
	n (%)	n (%)
Corticosteroid	194 (41%)	70 (57%)
Steroid-Sparing Agents		
Azathioprine	15 (3%)	2 (2%)
Chloroquine	0 (0%)	1 (1%)
Cyclophosphamide	2 (0.4%)	0 (0%)
Hydroxychloroquine	26 (5%)	7 (6%)
Leflunomide	5 (1%)	0 (0%)
Methotrexate	71 (15%)	16 (13%)
Mycophenolate mofetil	5 (1%)	2 (2%)
Sulfasalazine	1 (0.2%)	0 (0%)
Biologic Agents		
Abatacept	1 (0.2%)	0 (0%)
Adalimumab	3 (0.6%)	2 (2%)
Bevacizumab	1 (0.2%)	0 (0%)
Daclizumab	1 (0.2%)	0 (0%)
Etanercept	3 (0.6%)	0 (0%)
Golimumab	1 (0.2%)	0 (0%)
Infliximab	7 (1.5%)	1 (1%)
Tocilizumab	1 (0.2%)	0 (0%)

Table E3: State and Province breakdown of patients in U.S. and Canadian cohorts.

U.S. Cohort (N = 477)		Canadian Cohort (N = 122)	
State, n (%)		Province, n (%)	
Arizona	1 (0.2%)	British Columbia	19 (16%)
California	1 (0.2%)	Ontario	31 (25%)
Florida	2 (0.4%)	Quebec	71 (58%)
Massachusetts	1 (0.2%)	Saskatchewan	1 (1%)
Maryland	2 (0.4%)		
North Carolina	2 (0.4%)		
New York	5 (1.1%)		
Ohio	12 (2.5%)		
Pennsylvania	429 (89.9%)		
South Carolina	1 (0.2%)		
Tennessee	2 (0.4%)		
Texas	1 (0.2%)		
Virginia	2 (0.4%)		
Washington	1 (0.2%)		
West Virginia	15 (3.1%)		

Table E4: Patient demographics by U.S. or Canadian cohort with cohort broken down into patients with and without baseline FVC. Abbreviations: ADI, area deprivation index; CIMD, Canadian index of multiple deprivation; D_LCO, diffusion capacity for carbon monoxide; FVC, forced vital capacity; IQR, interquartile range; U.S., United States.

Patient Characteristics	U.S. Cohort		Canadian Cohort	
	With Baseline FVC	Without Baseline FVC	With Baseline FVC	Without Baseline FVC
	N = 389	N = 88	N = 102	N = 20
Age at diagnosis, median (IQR), years	49 (42 to 56)	49 (41 to 57)	52 (45 to 60)	53 (45 to 60)
Year of diagnosis, median (IQR), year	2010 (2006 to 2013)	2009 (2005 to 2011)	2016 (2013 to 2017)	2011 (2009 to 2015)
Male sex, n (%)	174 (45%)	33 (38%)	58 (57%)	9 (45%)
Self-reported race, n (%)				
White	280 (72%)	73 (83%)	93 (91%)	19 (95%)
Black	98 (25%)	12 (14%)	3 (3%)	0 (0%)
Asian	1 (0.3%)	0 (0%)	3 (3%)	1 (5%)
Indigenous*	1 (0.3%)	0 (0%)	1 (1%)	0 (0%)
Unknown	9 (2%)	3 (3%)	2 (2%)	0 (0%)
Smoking history, n (%)				
Never	209 (54%)	47 (53%)	50 (49%)	11 (55%)
Former	129 (33%)	29 (33%)	43 (42%)	8 (40%)
Current	28 (7%)	7 (8%)	9 (9%)	1 (5%)
Unknown	23 (6%)	5 (6%)	0 (0%)	0 (0%)
Extrapulmonary Manifestations at Initial Visit, n(%)	200 (51%)	38 (44%)	42 (41%)	7 (35%)
Skin	93 (24%)	16 (18%)	11 (11%)	20 (0%)
Liver	25 (6%)	2 (2%)	7 (7%)	1 (5%)
Spleen	5 (1%)	1 (1%)	2 (2%)	0 (0%)
Eyes	49 (13%)	10 (11%)	11 (11%)	3 (15%)
ENT	11 (3%)	3 (3%)	1 (1%)	1 (5%)
Salivary glands	7 (2%)	2 (2%)	2 (2%)	1 (5%)
Bones or joints	29 (7%)	6 (7%)	9 (9%)	0 (0%)
Bone marrow	3 (1%)	2 (2%)	0 (0%)	0 (0%)
Calcium-Vitamin D homeostasis	19 (5%)	3 (3%)	3 (3%)	1 (5%)
Muscle	3 (1%)	0 (0%)	1 (1%)	0 (0%)
Extrathoracic lymphadenopathy	6 (2%)	6 (7%)	5 (5%)	0 (0%)
Renal	2 (1%)	0 (0%)	1 (1%)	0 (0%)
Central nervous system	34 (9%)	8 (9%)	4 (4%)	0 (0%)
Cardiac	17 (4%)	6 (7%)	9 (9%)	1 (5%)
Other (gastrointestinal, genitourinary, etc)	8 (2%)	1 (1%)	2 (2%)	1 (5%)

Immunosuppressant Treatment Prior to Initial Visit, n(%)				
Corticosteroid (PO or IV)	163 (42%)	31 (35%)	62 (61%)	10 (50%)
Non-biologic steroid-sparing immunosuppressant	88 (23%)	18 (20%)	17 (17%)	3 (15%)
Biologic steroid-sparing immunosuppressant	13 (3%)	1 (3%)	1 (1%)	0 (0%)
ADI or CIMD, median score (IQR)	68 (48 to 83)	66 (49 to 78)	-0.14 (-0.51 to 0.23)	-0.02 (-0.45 to 0.33)
Baseline FVC % Predicted, median (IQR)**	83 (69 to 95)	NA	87 (73 to 96)	NA
Baseline DLCO % Predicted, median (IQR)***	75 (60 to 90)	NA	81 (73 to 93)	NA
Follow-up Duration, median (IQR), years	8.1 (4.7 to 12.4)	9.3 (5.0 to 12.4)	3.86 (2.52 to 6.73)	8.30 (3.89 to 10.90)
Final Outcome, n (%)				
Death	38 (10%)	13 (15%)	3 (3%)	1 (5%)
Lung Transplantation	11 (3%)	4 (5%)	0 (0%)	0 (0%)
Lost to follow-up or censored due to data extraction	340 (87%)	81 (71%)	99 (97%)	19 (95%)

*Includes Native American, American Indian, Alaskan First Nations, & other Indigenous persons in the U.S.; First Nations, Métis, Inuit, and other Indigenous persons in Canada.

**FVC was available for 82% of patients in the U.S. cohort and 84% in the Canadian cohort.

***DLCO was available for 79% of patients in the U.S. cohort and 71% in the Canadian cohort.

Table E5: Unadjusted, partially-adjusted, and fully-adjusted linear regression models evaluating the association between ADI or CIMD and baseline FVC or D_LCO. Partially-adjusted models are adjusted for age at diagnosis and sex, and fully-adjusted are additionally adjusted for smoking history and race. P-values <0.05 are **bolded** and <0.10 are *italicized*.

U.S. Cohort				Canadian Cohort			
Unadjusted FVC Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 388)				Continuous CIMD (N = 102)			
Continuous ADI	-0.13	-0.21, -0.05	0.002	Continuous CIMD	1.82	-4.78, 8.42	0.59
Quartiled ADI (N = 388)				Quartiled CIMD (N = 102)			
Quartile 1	<i>reference</i>			Quartile 1	<i>reference</i>		
Quartile 2	-1.12	-6.45, 4.22	0.68	Quartile 2	1.34	-8.94, 11.61	0.80
Quartile 3	-2.75	-7.94, 2.44	0.30	Quartile 3	-0.40	-10.57, 9.78	0.94
Quartile 4	-6.58	-11.81, -1.35	0.01	Quartile 4	2.80	-7.59, 13.18	0.59
Partially-Adjusted FVC Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 388)				Continuous CIMD (N = 102)			
Continuous ADI	-0.14	-0.22, -0.06	0.001	Continuous CIMD	2.47	-4.06, 8.99	0.46
Quartiled ADI (N = 388)				Quartiled CIMD (N = 102)			
Quartile 1	<i>reference</i>			Quartile 1	<i>reference</i>		
Quartile 2	-1.29	-6.64, 4.06	0.64	Quartile 2	2.01	-8.27, 12.29	0.70
Quartile 3	-3.00	-8.24, 2.23	0.26	Quartile 3	0.36	-9.67, 10.38	0.94
Quartile 4	-7.24	-12.56, -1.92	0.008	Quartile 4	4.76	-5.62, 15.14	0.37
Fully-Adjusted FVC Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 388)				Continuous CIMD (N = 102)			
Continuous ADI	-0.06	-0.14, 0.02	0.14	Continuous CIMD	2.27	-4.19, 8.74	0.49
Quartiled ADI (N = 388)				Quartiled CIMD (N = 102)			
Quartile 1	<i>reference</i>			Quartile 1	<i>reference</i>		
Quartile 2	-2.07	-7.04, 2.91	0.41	Quartile 2	0.73	-9.58, 11.05	0.89
Quartile 3	-3.00	-7.87, 1.86	0.23	Quartile 3	0.42	-9.74, 10.57	0.94
Quartile 4	-1.66	-6.80, 3.48	0.53	Quartile 4	3.09	-7.35, 13.53	0.56
Unadjusted D _L CO Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 374)				Continuous CIMD (N = 87)			
Continuous ADI	-0.22	-0.32, -0.12	<0.001	Continuous CIMD	-4.53	-12.73, 3.68	0.28
Quartiled ADI (N = 374)				Quartiled CIMD (N = 87)			
Quartile 1	<i>reference</i>			Quartile 1	<i>reference</i>		
Quartile 2	-6.39	-13.05, 0.26	<i>0.06</i>	Quartile 2	-0.40	-12.81, 12.01	0.95

Quartile 3	-7.13	-13.58, -0.67	0.03	Quartile 3	-8.83	-20.81, 3.16	0.15
Quartile 4	-14.72	-21.30, -8.14	<0.001	Quartile 4	-6.22	-19.40, 6.96	0.35
Partially-Adjusted D_LCO Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 374)				Continuous CIMD (N = 87)			
Continuous ADI	-0.17	-0.27, -0.07	<0.001	Continuous CIMD	-5.14	-13.30, 3.03	0.21
Quartiled ADI (N = 374)				Quartiled CIMD (N = 87)			
Quartile 1	<i>reference</i>			Quartile 1	<i>reference</i>		
Quartile 2	-4.47	-10.92, 1.99	0.17	Quartile 2	2.14	-10.45, 14.72	0.74
Quartile 3	-4.47	-10.76, 1.84	0.16	Quartile 3	-8.42	-20.31, 3.46	0.16
Quartile 4	-11.74	-18.22, -5.27	<0.001	Quartile 4	-5.34	-18.43, 7.74	0.42
Fully-Adjusted D_LCO Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 374)				Continuous CIMD (N = 87)			
Continuous ADI	-0.10	-0.19, -0.0004	0.049	Continuous CIMD	-5.38	-13.21, 2.45	0.18
Quartiled ADI (N = 374)				Quartiled CIMD (N = 87)			
Quartile 1	<i>reference</i>			Quartile 1	<i>reference</i>		
Quartile 2	-5.21	-11.33, 0.91	0.09	Quartile 2	1.95	-10.34, 14.24	0.75
Quartile 3	-4.51	-10.48, 1.46	0.14	Quartile 3	-5.61	-17.28, 6.07	0.34
Quartile 4	-6.80	-13.16, -0.44	0.04	Quartile 4	-7.47	-20.28, 5.33	0.25

Table E6: Unadjusted, partially-adjusted, and fully-adjusted linear mixed effects models with random intercept evaluating the association between ADI or CIMD and rate of change in FVC or D_LCO. Partially-adjusted models are adjusted for age at diagnosis and sex, and fully-adjusted are additionally adjusted for smoking history and race. P-values <0.05 are **bolded**.

U.S. Cohort				Canadian Cohort			
Unadjusted FVC Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 389)				Continuous CIMD (N = 102)			
Continuous ADI*time	-0.006	-0.010, -0.002	0.002	Continuous CIMD*time	-0.45	-0.80, -0.10	0.01
Quartiled ADI (N = 389)				Quartiled CIMD (N = 102)			
Quartile 1*time	<i>reference</i>			Quartile 1*time	<i>reference</i>		
Quartile 2*time	-0.06	-0.31, 0.20	0.67	Quartile 2*time	0.16	-0.42, 0.74	0.58
Quartile 3*time	-0.16	-0.40, 0.07	0.17	Quartile 3*time	-0.31	-0.76, 0.14	0.17
Quartile 4*time	-0.42	-0.65, -0.18	<0.001	Quartile 4*time	-0.79	-1.30, -0.27	0.003
Partially-Adjusted FVC Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 389)				Continuous CIMD (N = 102)			
Continuous ADI*time	-0.006	-0.010, -0.002	0.002	Continuous CIMD*time	-0.47	-0.82, -0.11	0.01
Quartiled ADI (N = 389)				Quartiled CIMD (N = 102)			
Quartile 1*time	<i>reference</i>			Quartile 1*time	<i>reference</i>		
Quartile 2*time	-0.10	-0.37, 0.17	0.47	Quartile 2*time	0.05	-0.58, 0.69	0.87
Quartile 3*time	-0.16	-0.40, 0.08	0.20	Quartile 3*time	-0.34	-0.83, 0.15	0.17
Quartile 4*time	-0.45	-0.69, -0.20	<0.001	Quartile 4*time	-0.84	-1.39, -0.30	0.002
Fully-Adjusted FVC Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 389)				Continuous CIMD (N = 102)			
Continuous ADI*time	-0.005	-0.009, -0.0003	0.04	Continuous CIMD*time	-0.47	-0.84, -0.10	0.01
Quartiled ADI (N = 389)				Quartiled CIMD (N = 102)			
Quartile 1*time	<i>reference</i>			Quartile 1*time	<i>reference</i>		
Quartile 2*time	-0.07	-0.34, 0.20	0.59	Quartile 2*time	0.06	-0.59, 0.72	0.85
Quartile 3*time	-0.10	-0.35, 0.16	0.46	Quartile 3*time	-0.40	-1.01, 0.20	0.19
Quartile 4*time	-0.36	-0.63, -0.10	0.007	Quartile 4*time	-0.80	-1.37, -0.24	0.006
Unadjusted D _L CO Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 386)				Continuous CIMD (N = 99)			
Continuous ADI*time	-0.006	-0.01, -0.001	0.02	Continuous CIMD*time	-0.53	-1.05, -0.01	0.045
Quartiled ADI (N = 386)				Quartiled CIMD (N = 99)			
Quartile 1*time	<i>reference</i>			Quartile 1*time	<i>reference</i>		
Quartile 2*time	-0.55	-0.87, -0.23	<0.001	Quartile 2*time	0.11	-0.73, 0.95	0.80

Quartile 3*time	-0.33	-0.62, -0.03	0.03	Quartile 3*time	-0.37	-1.07, 0.32	0.29
Quartile 4*time	-0.37	-0.67, -0.07	0.02	Quartile 4*time	-0.65	-1.45, 0.14	0.11
Partially-Adjusted D_LCO Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 386)				Continuous CIMD (N = 99)			
Continuous ADI*time	-0.005	-0.01, -0.00003	0.049	Continuous CIMD*time	-0.57	-1.10, -0.05	0.03
Quartiled ADI (N = 386)				Quartiled CIMD (N = 99)			
Quartile 1*time	<i>reference</i>			Quartile 1*time	<i>reference</i>		
Quartile 2*time	-0.63	-0.97, -0.29	<0.001	Quartile 2*time	-0.01	-0.94, 0.92	0.98
Quartile 3*time	-0.29	-0.60, 0.01	0.06	Quartile 3*time	-0.51	-1.25, 0.23	0.18
Quartile 4*time	-0.37	-0.69, -0.06	0.02	Quartile 4*time	-0.70	-1.51, 0.12	0.095
Fully-Adjusted D_LCO Model							
	β	95% CI	P-value		β	95% CI	P-value
Continuous ADI (N = 386)				Continuous CIMD (N = 99)			
Continuous ADI*time	-0.008	-0.010, -0.003	0.002	Continuous CIMD*time	-0.39	-0.94, 0.15	0.16
Quartiled ADI (N = 386)				Quartiled CIMD (N = 99)			
Quartile 1*time	<i>reference</i>			Quartile 1*time	<i>reference</i>		
Quartile 2*time	-0.71	-1.05, -0.37	<0.001	Quartile 2*time	-0.04	-0.99, 0.91	0.93
Quartile 3*time	-0.45	-0.77, -0.14	0.005	Quartile 3*time	-0.35	-1.30, 0.60	0.47
Quartile 4*time	-0.54	-0.87, -0.21	0.001	Quartile 4*time	-0.61	-1.45, 0.24	0.16

Table E7: Unadjusted and fully-adjusted competing hazards models evaluating the impact of ADI on survival in U.S. cohort with lung transplant as competing risk for death. Abbreviations: ADI, area deprivation index; D_LCO, diffusion capacity for carbon monoxide; FVC, forced vital capacity; HR, hazard ratio. Covariates with significant HR are **bolded**.

Continuous Models			Quartiled Models		
	HR	95% CI		HR	95% CI
Continuous ADI Unadjusted Model – Mortality Outcome (N = 477)			Quartiled ADI Unadjusted Model – Mortality Outcome (N = 477)		
Continuous ADI	1.00	0.99, 1.02	Quartile 1	<i>reference</i>	
			Quartile 2	1.19	0.55, 2.56
			Quartile 3	1.20	0.56, 2.56
			Quartile 4	1.11	0.49, 2.52
Continuous ADI Unadjusted Model – Transplant Outcome (N = 477)			Quartiled ADI Unadjusted Model – Transplant Outcome (N = 477)		
Continuous ADI	1.01	0.98, 1.03	Quartile 1	<i>reference</i>	
			Quartile 2	1.47	0.33, 6.50
			Quartile 3	1.41	0.32, 6.21
			Quartile 4	1.60	0.36, 7.15
Continuous ADI Fully-Adjusted Model – Mortality Outcome (N = 353)			Quartiled ADI Fully-Adjusted Model – Mortality Outcome (N = 353)		
Continuous ADI	1.01	0.99, 1.02	Quartile 1	<i>Reference</i>	
			Quartile 2	1.38	0.46, 4.15
			Quartile 3	1.88	0.65, 5.38
			Quartile 4	0.97	0.29, 3.19
Female sex	0.32	0.14, 0.70	Female sex	0.30	0.14, 0.65
Ever smoking	0.46	0.20, 1.09	Ever smoking	0.43	0.17, 1.03
Age at diagnosis	1.09	1.04, 1.13	Age at diagnosis	1.08	1.04, 1.13
Non-White race	0.79	0.34, 1.81	Non-White race	0.89	0.40, 1.99
Baseline FVC	1.02	0.99, 1.04	Baseline FVC	1.02	0.99, 1.05
Baseline D _L CO	0.96	0.93, 0.99	Baseline D _L CO	0.96	0.93, 0.99
Continuous ADI Fully-Adjusted Model – Transplant Outcome (N = 353)			Quartiled ADI Fully-Adjusted Model – Transplant Outcome (N = 353)		
Continuous ADI	1.00	0.97, 1.03	Quartile 1	<i>reference</i>	
			Quartile 2	1.48	0.18, 12.19
			Quartile 3	1.66	0.20, 13.80
			Quartile 4	1.36	0.29, 6.50
Female sex	0.74	0.21, 2.63	Female sex	0.63	0.15, 2.75
Ever smoking	0.79	0.24, 2.56	Ever smoking	0.80	0.24, 2.69
Age at diagnosis	1.00	0.95, 1.06	Age at diagnosis	1.00	0.95, 1.06
Non-White race	0.15*	0.03, 0.74	Non-White race	0.15	0.04, 0.57
Baseline FVC	0.99	0.95, 1.03	Baseline FVC	0.99	0.95, 1.04
Baseline D _L CO	0.92	0.87, 0.97	Baseline D _L CO	0.92	0.87, 0.97

* Interpretation: As compared to patients of White race, patients of non-White race have 0.15 the likelihood of experiencing the “hazard” of lung transplant. I.e. they are approximately 85% less likely than White individuals to receive transplant.